LIXTE reports Roche-backed trial, new CMO, and SCLC trial termination

LIXTE BIOTECHNOLOGY HOLDINGS, INC.

New clinical trial with Netherlands Cancer Institute, supported by Roche, testing LB-100 + atezolizumab in metastatic colorectal cancer.
Dr. Jan Schellens appointed Chief Medical Officer effective Aug 1, 2024; 25+ years oncology drug development experience.
Preclinical data in EMBO Reports shows LB-100 can turn immunologically 'cold' tumors 'hot', enhancing immunotherapy benefit.
Small cell lung cancer trial at City of Hope terminated due to limited patient accrual; exploring alternative sites.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.